PMID- 23838481
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20220330
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 87
IP  - 2
DP  - 2013 Aug
TI  - Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus.
PG  - 101-11
LID - S1040-8428(13)00118-2 [pii]
LID - 10.1016/j.critrevonc.2013.05.015 [doi]
AB  - Patients with breast cancer face substantial challenges to bone health from bone 
      metastases, as well as from chemotherapy and endocrine therapies that generally 
      elicit disease control at the cost of increased bone turnover. Consequently, 
      maintaining bone health is of critical importance for these patients. Recently 
      reported results from BOLERO-2 showed significant clinical benefits with adding 
      everolimus to exemestane therapy in postmenopausal women with 
      estrogen-receptor-positive breast cancer recurring or progressing despite 
      nonsteroidal aromatase inhibitor therapy. Moreover, exploratory analyses from 
      BOLERO-2 showed that adding everolimus may have beneficial effects on bone 
      turnover and progressive disease in bone in this patient population. These 
      results are supported by preclinical studies in which mTOR inhibition was 
      associated with decreased osteoclast survival and activity. Thus, everolimus 
      therapy may be able to ameliorate the negative effects of estrogen suppression on 
      bone health. This review discusses the effects of mTOR inhibition on bone health 
      during endocrine therapy.
CI  - Copyright (c) 2013 The Authors. Published by Elsevier Ireland Ltd.. All rights 
      reserved.
FAU - Hadji, Peyman
AU  - Hadji P
AD  - Department of Gynecology, Philipps-University of Marburg, Marburg, Germany. 
      hadji@med.uni-marburg.de
FAU - Coleman, Robert
AU  - Coleman R
FAU - Gnant, Michael
AU  - Gnant M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130706
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antineoplastic Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/therapeutic use
MH  - Bone Neoplasms/drug therapy/metabolism/secondary
MH  - Bone and Bones/*drug effects/*metabolism
MH  - Breast Neoplasms/drug therapy/metabolism/pathology
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Sirolimus/*analogs & derivatives/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/metabolism
OTO - NOTNLM
OT  - Aromatase inhibitors
OT  - Bone
OT  - Breast cancer
OT  - Everolimus
OT  - Postmenopausal women
OT  - mTOR
EDAT- 2013/07/11 06:00
MHDA- 2014/01/31 06:00
CRDT- 2013/07/11 06:00
PHST- 2013/03/14 00:00 [received]
PHST- 2013/05/22 00:00 [revised]
PHST- 2013/05/31 00:00 [accepted]
PHST- 2013/07/11 06:00 [entrez]
PHST- 2013/07/11 06:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - S1040-8428(13)00118-2 [pii]
AID - 10.1016/j.critrevonc.2013.05.015 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2013 Aug;87(2):101-11. doi: 
      10.1016/j.critrevonc.2013.05.015. Epub 2013 Jul 6.